Skip to content

vědecké publikace

Klinické využití ketaminu

Přehled vědeckých publikací

Depresivní onemocnění a ketamin

  • Andrade, C. (2019). Oral ketamine for depression, 1: Pharmacologic considerations and clinical evidence. J Clin Psychiatry, 80(2). doi: 10.4088/JCP.19f12820
  • Banov, M. D., Young, J. R., Dunn, T., & Szabo, S. T. (2019). Efficacy and safety of ketamine in the management of anxiety and anxiety spectrum disorders: A review of the literature. CNS Spectr, 1-12. doi: 10.1017/S1092852919001238
  • Bell, R. F. (2012). Ketamine for chronic noncancer pain: Concerns regarding toxicity. Curr Opin Support Palliat Care, 6(2), 183-187. doi: 10.1097/SPC.0b013e328352812c
  • Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000). Antidepressant effects of ketamine in depressed patients. Biol Psychiatry, 47(4), 351-354. doi: 10.1016/s0006-3223(99)00230-9
  • Dakwar, E., Anerella, C., Hart, C. L., Levin, F. R., Mathew, S. J., & Nunes, E. V. (2014). Therapeutic infusions of  ketamine: Do the psychoactive effects matter? Drug Alcohol Depend, 136, 153-157. doi: 10.1016/j.drugalcdep.2013.12.019
  • Dakwar, E., Levin, F., Hart, C. L., Basaraba, C., Choi, J., Pavlicova, M., & Nunes, E. V. (2020). A single ketamine infusion combined with motivational enhancement therapy for alcohol use disorder: A randomized midazolam-controlled pilot trial. Am J Psychiatry, 177(2), 125-133. doi: 10.1176/appi.ajp.2019.19070684
  • Dakwar, E., Nunes, E. V., Hart, C. L., Foltin, R. W., Mathew, S. J., Carpenter, K. M., . . . Levin, F. R. (2019). A single ketamine infusion combined with mindfulness-based behavioral modification to treat cocaine dependence: A randomized clinical trial. Am J Psychiatry, 176(11), 923-930. doi: 10.1176/appi.ajp.2019.18101123
  • Dittrich, A. (1998). The standardized psychometric assessment of altered states of consciousness (ascs) in humans. Pharmacopsychiatry, 31 Suppl 2, 80-84. doi: 10.1055/s-2007-979351
  • Dore, J., Turnipseed, B., Dwyer, S., Turnipseed, A., Andries, J., Ascani, G., . . . Wolfson, P. (2019). Ketamine assisted psychotherapy (kap): Patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy. J Psychoactive Drugs, 51(2), 189-198. doi: 10.1080/02791072.2019.1587556
  • Gao, M., Rejaei, D., & Liu, H. (2016). Ketamine use in current clinical practice. Acta Pharmacol Sin, 37(7), 865-872. doi: 10.1038/aps.2016.5 Horacek, J., Brunovsky, M., Novak, T., Tislerova, B., Palenicek, T., Bubenikova-Valesova, V., . . . Hoschl, C. (2010). Subanesthetic dose of ketamine decreases prefrontal theta cordance in healthy volunteers: Implications for antidepressant effect. Psychol Med, 40(9), 1443-1451. doi: 10.1017/S0033291709991619
  • Horacek, J., Lipski, M. , & Sos, P. (2016). Příběh jedné molekuly. Čtyři tváře ketaminu. Vesmír, 95(5), 272–275.
  • Horacek, J., Palenicek, T., Malek, J., Scigel, V., Kurzova, A., & Hess, L. (2012). The influence of clonidine on oral ketamine-midazolam premedication in intellectually disabled patients indicated for dental procedures: Double-blind comparison of two sedation regimes. Neuro Endocrinol Lett, 33(4), 380-384.
  • Iglewicz, A., Morrison, K., Nelesen, R. A., Zhan, T., Iglewicz, B., Fairman, N., . . . Irwin, S. A. (2015). Ketamine for the treatment of depression in patients receiving hospice care: A retrospective medical record review of thirty-one cases. Psychosomatics, 56(4), 329-337. doi: 10.1016/j.psym.2014.05.005
  • Kishimoto, T., Chawla, J. M., Hagi, K., Zarate, C. A., Kane, J. M., Bauer, M., & Correll, C. U. (2016). Single-dose infusion ketamine and non-ketamine n-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: A meta-analysis of efficacy, safety and time trajectories. Psychol Med, 46(7), 1459-1472. doi: 10.1017/S0033291716000064
  • Krupitsky, E., Burakov, A., Romanova, T., Dunaevsky, I., Strassman, R., & Grinenko, A. (2002). Ketamine psychotherapy for heroin addiction: Immediate effects and two-year follow-up. J Subst Abuse Treat, 23(4), 273-283. doi: 10.1016/s0740-5472(02)00275-1
  • Krupitsky, E. M., Burakov, A. M., Dunaevsky, I. V., Romanova, T. N., Slavina, T. Y., & Grinenko, A. Y. (2007). Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence. J Psychoactive Drugs, 39(1), 13-19. doi: 10.1080/02791072.2007.10399860
  • Liao, Y., Tang, J., Corlett, P. R., Wang, X., Yang, M., Chen, H., . . . Fletcher, P. C. (2011). Reduced dorsal prefrontal gray matter after chronic ketamine use. Biol Psychiatry, 69(1), 42-48. doi:  10.1016/j.biopsych.2010.08.030
  • Liu, S. Y. W., Ng, S. K. K., Tam, Y. H., Yee, S. C. H., Lai, F. P. T., Hong, C. Y. L., . . . Ng, C. F. (2017). Clinical pattern and prevalence of upper gastrointestinal toxicity in patients abusing ketamine. J Dig Dis, 18(9), 504-510. doi: 10.1111/1751-2980.12512
  • Luckenbaugh, D. A., Niciu, M. J., Ionescu, D. F., Nolan, N. M., Richards, E. M., Brutsche, N. E., . . . Zarate, C. A. (2014). Do the dissociative side effects of ketamine mediate its antidepressant effects? J Affect Disord, 159, 56-61. doi: 10.1016/j.jad.2014.02.017
  • Morgan, C. J., Curran, H. V., & Independent Scientific Committee on, Drugs. (2012). Ketamine use: A review. Addiction, 107(1), 27-38. doi: 10.1111/j.1360-0443.2011.03576.x
  • Muetzelfeldt, L., Kamboj, S. K., Rees, H., Taylor, J., Morgan, C. J., & Curran, H. V. (2008). Journey through the k-hole: Phenomenological aspects of ketamine use. Drug Alcohol Depend, 95(3), 219-229. doi: 10.1016/j.drugalcdep.2008.01.024
  • Olney, J. W., Labruyere, J., & Price, M. T. (1989). Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science, 244(4910), 1360-1362. doi: 10.1126/science.2660263
  • Olney, J. W., Labruyere, J., Wang, G., Wozniak, D. F., Price, M. T., & Sesma, M. A. (1991). Nmda antagonist neurotoxicity: Mechanism and prevention. Science, 254(5037), 1515-1518. doi: 10.1126/science.1835799
  • Olney, J. W., Price, M. T., Fuller, T. A., Labruyere, J., Samson, L., Carpenter, M., & Mahan, K. (1986). The anti-excitotoxic effects of certain anesthetics, analgesics and sedative-hypnotics. Neurosci Lett, 68(1), 29-34. doi: 10.1016/0304-3940(86)90224-7
  • Peltoniemi, M. A., Hagelberg, N. M., Olkkola, K. T., & Saari, T. I. (2016). Ketamine: A review of clinical pharmacokinetics and pharmacodynamics in anesthesia and pain therapy. Clin Pharmacokinet, 55(9), 1059-1077. doi: 10.1007/s40262-016-0383-6
  • Rosenblat, J. D., Carvalho, A. F., Li, M., Lee, Y., Subramanieapillai, M., & McIntyre, R. S. (2019). Oral ketamine for depression: A systematic review. J Clin Psychiatry, 80(3). doi: 10.4088/JCP.18r12475
  • Shahani, R., Streutker, C., Dickson, B., & Stewart, R. J. (2007). Ketamine-associated ulcerative cystitis: A new clinical entity. Urology, 69(5), 810-812. doi: 10.1016/j.urology.2007.01.038
  • Sos, P., Klirova, M., Novak, T., Kohutova, B., Horacek, J., & Palenicek, T. (2013). Relationship of ketamine’s antidepressant and psychotomimetic effects in unipolar depression. Neuro Endocrinol Lett, 34(4), 287-293.
  • Vollenweider, F. X., & Kometer, M. (2010). The neurobiology of psychedelic drugs: Implications for the treatment of mood disorders. Nat Rev Neurosci, 11(9), 642-651. doi: 10.1038/nrn2884
  • Wan, L. B., Levitch, C. F., Perez, A. M., Brallier, J. W., Iosifescu, D. V., Chang, L. C., . . . Murrough, J. W. (2015). Ketamine safety and tolerability in clinical trials for treatment-resistant depression. J Clin Psychiatry, 76(3), 247-252. doi: 10.4088/JCP.13m08852
  • Xu, J., & Lei, H. (2014). Ketamine-an update on its clinical uses and abuses. CNS Neurosci Ther, 20(12), 1015-1020. doi: 10.1111/cns.12363

Úzkostné poruchy (GAD, SAD) a ketamin

  • Glue, P., Medlicott, N. J., Harland, S., Neehoff, S., Anderson-Fahey, B., Le Nedelec, M., … & McNaughton, N. (2017). Ketamine’s dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders. Journal of Psychopharmacology, 31(10), 1302-1305.
  • Glue, P., Neehoff, S., Sabadel, A., Broughton, L., Le Nedelec, M., Shadli, S., … & Medlicott, N. J. (2019). Effects of ketamine in patients with treatment-refractory generalized anxiety and social anxiety disorders: exploratory double-blind psychoactive-controlled replication study. Journal of Psychopharmacology, 34(3), 267-272.
  • Glue, P., Neehoff, S. M., Medlicott, N. J., Gray, A., Kibby, G., & McNaughton, N. (2018). Safety and efficacy of maintenance ketamine treatment in patients with treatment-refractory generalised anxiety and social anxiety disorders. Journal of Psychopharmacology, 32(6), 663-667.
  • Taylor, J. H., Landeros-Weisenberger, A., Coughlin, C., Mulqueen, J., Johnson, J. A., Gabriel, D., … & Bloch, M. H. (2018). Ketamine for social anxiety disorder: a randomized, placebo-controlled crossover trial. Neuropsychopharmacology, 43(2), 325-333.
  • Salloum, N. C., Fava, M., Freeman, M. P., Flynn, M., Hoeppner, B., Hock, R. S., … & Papakostas, G. I. (2019). Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment‐resistant depression. Depression and anxiety, 36(3), 235-243.
  • McIntyre, R. S., Lipsitz, O., Rodrigues, N. B., Lee, Y., Cha, D. S., Vinberg, M., … & Rosenblat, J. D. (2020). The effectiveness of ketamine on anxiety, irritability, and agitation: implications for treating mixed features in adults with major depressive or bipolar disorder. Bipolar disorders, 22(8), 831-840.

Obsedantně kompulzivní porucha (OCD) a ketamin

  • Adams, T.G.; Bloch, M.H.; Pittenger, C. Intranasal Ketamine and Cognitive-Behavioral Therapy for Treatment-Refractory Obsessive-Compulsive Disorder. J. Clin. Psychopharmacol. 2017, 37, 269–271.
  • Bloch, M.H.; Wasylink, S.; Landeros-Weisenberger, A.; Panza, K.E.; Billingslea, E.; Leckman, J.F.; Krystal, J.H.; Bhagwagar, Z.; Sanacora, G.; Pittenger, C. Effects of ketamine in treatment-refractory obsessive-compulsive disorder. Biol. Psychiatry 2012, 72, 964–970.
  • Niciu, M.J.; Grunschel, B.D.; Corlett, P.R.; Pittenger, C.; Bloch, M.H. Two cases of delayed-onset suicidal ideation, dysphoria and anxiety after ketamine infusion in patients with obsessive-compulsive disorder and a history of major depressive disorder. J. Psychopharmacol. 2013, 27, 651–654.
  • Rodriguez, C.I.; Kegeles, L.S.; Levinson, A.; Feng, T.; Marcus, S.M.; Vermes, D.; Flood, P.; Simpson, H.B. Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: Proof-of-concept. Neuropsychopharmacology 2013, 38, 2475–2483.
  • Rodriguez, C.I.; Wheaton, M.; Zwerling, J.; Steinman, S.S.; Sonnenfeld, D.; Galfalvy, H.; Blair Simpson, H. Can Exposure-Based CBT Extend IV Ketamine’s Effects in Obsessive-Compulsive Disorder? An Open-Label Trial. J. Clin. Psychiatry 2016, 77, 408–409.
  • Rodriguez, C.I.; Lapidus, K.; Zwerling, J.; Levinson, A.; Mahnke, A.; Steinman, S.A.; Kalanthroff, E.; Simpson, H.B. Challenges in Testing Intranasal Ketamine in Obsessive-Compulsive Disorder. J. Clin. Psychiatry 2017, 78, 466–467.
  • Rodriguez, C.I.; Kegeles, L.S.; Levinson, A.; Ogden, R.T.; Mao, X.; Milak, M.S.; Vermes, D.; Xie, S.; Hunter, L.; Flood, P.; et al. In vivo effects of ketamine on glutamate-glutamine and gamma-aminobutyric acid in obsessive-compulsive disorder: Proof of concept. Psychiatry Res. 2015, 233, 141–147.
  • Rodriguez, C.I.; Levinson, A.; Zwerling, J.; Vermes, D.; Simpson, H.B. Open-Label trial on the effects of memantine in adults with obsessive-compulsive disorder after a single ketamine infusion. J. Clin. Psychiatry 2016, 77, 688–689.
  • Rodriguez, C.I.; Kegeles, L.S.; Flood, P.; Simpson, H.B. Rapid resolution of obsessions after an infusion of intravenous ketamine in a patient with treatment-resistant obsessive-compulsive disorder. J. Clin. Psychiatry 2011, 72, 567–569.
  • Sharma, L.P.; Thamby, A.; Balachander, S.; Janardhanan, C.N.; Jaisoorya, T.S.; Arumugham, S.S.; Reddy, Y. Clinical utility of repeated intravenous ketamine treatment for resistant obsessive-compulsive disorder. Asian J. Psychiatry 2020, 52, 102183.

Poruchy příjmu potravy (PPP) a ketamin

  • Hermens, D. F., Simcock, G., Dutton, M., Bouças, A. P., Can, A. T., Lilley, C., & Lagopoulos, J. (2020). Anorexia nervosa, zinc deficiency and the glutamate system: The ketamine option. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 101, 109921.
  • Murray, S. L., & Holton, K. F. (2021). Post-traumatic stress disorder may set the neurobiological stage for eating disorders: A focus on glutamatergic dysfunction. Appetite, 167, 105599.
  • Keeler, J. L., Treasure, J., Juruena, M. F., Kan, C., & Himmerich, H. (2021). Ketamine as a Treatment for Anorexia Nervosa: A Narrative Review. Nutrients, 13(11), 4158.
  • Keeler, J. L., Treasure, J., Juruena, M. F., Kan, C., & Himmerich, H. (2021). Ketamine as a Treatment for Anorexia Nervosa: A Narrative Review. Nutrients, 13(11), 4158.
  • Mills, I. H., Park, G. R., Manara, A. R., & Merriman, R. J. (1998). Treatment of compulsive behaviour in eating disorders with intermittent ketamine infusions. QJM: monthly journal of the Association of Physicians, 91(7), 493-503.
  • Scolnick, B., Zupec-Kania, B., Calabrese, L., Aoki, C., & Hildebrandt, T. (2020). Remission from chronic anorexia nervosa with ketogenic diet and ketamine: case report. Frontiers in psychiatry, 763.
  • Dechant, E., Boyle, B., & Ross, R. A. (2020). Ketamine in a Patient with Comorbid Anorexia and MDD. Journal of Womens Health and Development, 3(3), 373-375.
  • Schwartz, T., Trunko, M. E., Feifel, D., Lopez, E., Peterson, D., Frank, G. K., & Kaye, W. (2021). A longitudinal case series of IM ketamine for patients with severe and enduring eating disorders and comorbid treatment‐resistant depression. Clinical case reports, 9(5), e03869.
  • Ragnhildstveit, A., Jackson, L. K., Cunningham, S., Good, L., Tanner, Q., Roughan, M., & Henrie-Barrus, P. (2021). Case Report: Unexpected Remission From Extreme and Enduring Bulimia Nervosa With Repeated Ketamine Assisted Psychotherapy. Frontiers in Psychiatry, 12.

Posttraumatická stresová porucha (PTSD) a ketamin

  • Jumaili, W. A., Trivedi, C., Chao, T., Kubosumi, A., & Jain, S. (2022). The safety and efficacy of ketamine NMDA receptor blocker as a therapeutic intervention for PTSD review of a randomized clinical trial. Behavioural brain research, 424, 113804.
  • Feder, A., Parides, M. K., Murrough, J. W., Perez, A. M., Morgan, J. E., Saxena, S., Kirkwood, K., Aan Het Rot, M., Lapidus, K. A., Wan, L. B., Iosifescu, D., & Charney, D. S. (2014). Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA psychiatry, 71(6), 681–688.
  • Feder, A., Costi, S., Rutter, S. B., Collins, A. B., Govindarajulu, U., Jha, M. K., Horn, S. R., Kautz, M., Corniquel, M., Collins, K. A., Bevilacqua, L., Glasgow, A. M., Brallier, J., Pietrzak, R. H., Murrough, J. W., & Charney, D. S. (2021). A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder. The American journal of psychiatry, 178(2), 193–202.
  • Pradhan, B., Mitrev, L., Moaddell, R., & Wainer, I. W. (2018). d-Serine is a potential biomarker for clinical response in treatment of post-traumatic stress disorder using (R,S)-ketamine infusion and TIMBER psychotherapy: A pilot study. Biochimica et biophysica acta. Proteins and proteomics, 1866(7), 831–839.
  • Dadabayev, A. R., Joshi, S. A., Reda, M. H., Lake, T., Hausman, M. S., Domino, E., & Liberzon, I. (2020). Low Dose Ketamine Infusion for Comorbid Posttraumatic Stress Disorder and Chronic Pain: A Randomized Double-Blind Clinical Trial. Chronic stress (Thousand Oaks, Calif.), 4, 2470547020981670.
  • Abdallah, C. G., Roache, J. D., Averill, L. A., Young-McCaughan, S., Martini, B., Gueorguieva, R., Amoroso, T., Southwick, S. M., Guthmiller, K., López-Roca, A. L., Lautenschlager, K., Mintz, J., Litz, B. T., Williamson, D. E., Keane, T. M., Peterson, A. L., Krystal, J. H., & Consortium to Alleviate PTSD (2019). Repeated ketamine infusions for antidepressant-resistant PTSD: Methods of a multicenter, randomized, placebo-controlled clinical trial. Contemporary clinical trials, 81, 11–18.
  • Albott, C. S., Lim, K. O., Forbes, M. K., Erbes, C., Tye, S. J., Grabowski, J. G., Thuras, P., Batres-Y-Carr, T. M., Wels, J., & Shiroma, P. R. (2018). Efficacy, Safety, and Durability of Repeated Ketamine Infusions for Comorbid Posttraumatic Stress Disorder and Treatment-Resistant Depression. The Journal of clinical psychiatry, 79(3), 17m11634.
  • Shiroma, P. R., Thuras, P., Wels, J., Erbes, C., Kehle-Forbes, S., & Polusny, M. (2020). A Proof-of-Concept Study of Subanesthetic Intravenous Ketamine Combined With Prolonged Exposure Therapy Among Veterans With Posttraumatic Stress Disorder. The Journal of clinical psychiatry, 81(6), 20l13406.
  • Hartberg, J., Garrett-Walcott, S., & De Gioannis, A. (2018). Impact of oral ketamine augmentation on hospital admissions in treatment-resistant depression and PTSD: a retrospective study. Psychopharmacology, 235(2), 393–398.
  • Davis, A. K., Mangini, P., & Xin, Y. (2021). Ketamine-assisted psychotherapy for trauma-exposed patients in an outpatient setting: A clinical chart review study, Journal of Psychedelic Studies, 5(2), 94-102. Retrieved Apr 11, 2022, from
  • Keizer, B. M., Roache, J. D., Jones, J. R., Kalpinski, R. J., Porcerelli, J. H., & Krystal, J. H. (2020). Continuous Ketamine Infusion for Pain as an Opportunity for Psychotherapy for PTSD: A Case Series of Ketamine-Enhanced Psychotherapy for PTSD and Pain (KEP-P2). Psychotherapy and psychosomatics, 89(5), 326–329.
  • Halstead, M., Reed, S., Krause, R., & Williams, M. T. (2021). Ketamine-Assisted Psychotherapy for PTSD Related to Racial Discrimination. Clinical Case Studies, 20(4), 310–330.

Kdo stojí za klinikou psyon?

Za projektem psychedelické kliniky stojí přední vědci v oblasti duševního zdraví, neurovědci, lékaři a psychologové. Využíváme širokou paletu směrů a přístupů s cílem efektivní pomoci při psychických, vztahových, či psychosomatických potížích.

prof. MUDr. Jiří Horáček, Ph.D., FCMA

náměstek pro vědu a výzkum v Národním ústavu pro duševní zdraví, lékař, výzkumný pracovník, pedagog 3. LF UK

MUDr. Tomáš Páleníček, Ph.D.

výzkumný pracovník v Národním ústavu pro duševní zdraví, lékař, pedagog 3. LF UK

MUDr. Martin Brunovský, Ph.D.

vedoucí výzkumného programu v Národním ústavu pro duševní zdraví, pedagog 3. LF UK, vedoucí lékař, výzkumný pracovník

MUDr. Filip Tylš, Ph.D.

výzkumný pracovník v Národním ústavu pro duševní zdraví, lékař, pedagog 3. LF UK, psychoterapeut

Mgr. et Mgr. Stanislav Milotinský

psycholog v Psychiatrické nemocnici Bohnice v Praze, psychoterapeut, Ph.D student

Ing. Václav Štrupl

úspěšný podnikatel, zakladatel fondu Miton Psychonauts věnující se oblasti duševního zdraví

Máte pocit, že by léčba KAP mohla být pro Vás?
Dejte nám vědět a my se během pár hodin ozveme.